We narrowed to 1,581 results for: FLP

#121675-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Sept. 27, 2023

Academic Institutions and Nonprofits only

#137156-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-iC++-EYFP (#137156). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-iC++-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 25, 2020

Academic Institutions and Nonprofits only

#137120-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (#137120). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Cre recombinase (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#171027-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-ChrimsonR-tdTomato (#171027). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-ChrimsonR-tdTomato plasmid DNA. Flp-dependent, Ef1a-driven expression of ChrimsonR-tdTomato fusion for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

July 21, 2023

Academic Institutions and Nonprofits only

#137148-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-Arch3.3-p2a-EYFP (#137148). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-Arch3.3-p2a-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of Arch3.3-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#137155-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-iC++-EYFP (#137155). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-iC++-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Dec. 1, 2020

Academic Institutions and Nonprofits only

#137130-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-BFP (#137130). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-BFP plasmid DNA. EF1a-driven, Cre-dependent expression of BFP (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

March 19, 2021

Academic Institutions and Nonprofits only

#55650-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn Con/Fon EYFP (#55650). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon EYFP plasmid DNA. Synapsin driven, Cre and Flp-dependent EYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Sept. 8, 2020

Academic Institutions and Nonprofits only